Any current/future new fundraising through debt or equity?

The company has not indicated any current or planned new fundraising through debt or equity. The balance sheet remains net debt-free with cash and cash equivalents of INR398 million as of FY '23. During the year, Vimta Labs repaid INR44 million of debt, reducing outstanding borrowings to INR150 million, with a very low debt-to-equity ratio of 0.05x. Capital expenditure plans (around INR60 crores for capacity doubling at Genome Valley) are being funded from internal accruals and routine capex aligned with depreciation. No mention of raising funds externally for growth or capex was made; focus i

Any current/future capex/capital investment/strategic investment?

Vimta Labs is undertaking a major capex of INR 60 crores to double capacities at the Genome Valley facility in Hyderabad, expected to complete by March FY '24. (Page 11, 16) This INR 60 crores capex is specifically for infrastructure/building expansion; equipment will be purchased as needed separately. (Page 7, 11) Approximately 20% of the INR 60 crores capex was spent in FY '23, with the remainder planned for FY '24. (Page 7) Additional ongoing annual capex aligns with depreciation expenses to buy new technologies, replace equipment, and expand capacities incrementally. (Page 7) Vimta Lab

Future growth expectations in sales/revenue/volumes?

Margins expected to improve going forward, driven primarily by volume growth across businesses (Page 17). FY '24 growth target aims to improve upon last year's rate despite some capacity constraints, especially in pharma (Page 10). Pharma segment capacity is severely constrained currently but expected to be managed until new facilities come online by Q4 FY '24 (Page 17). Electronic and electrical testing division expected to scale up, potentially adding capacity (a chamber) by 2025-26, targeting INR30-40 crores revenue in a couple of years (Pages 9, 13). Food division expected to cross

Future growth expectations in earnings/operating earnings/profits/EPS?

Vimta Labs expects better margins going forward driven primarily by volume growth across business segments. FY '24 growth target aims to improve over FY '23 despite capacity constraints, with strong growth particularly in pharma and food testing. Preclinical & clinical research and large molecule services (biologics) are emerging as promising growth drivers. Electronics and electrical testing segment is expected to scale up steadily with capacity expansions planned by 2025-26. Capacity expansion in Genome Valley (INR 60 crores capex) to complete by end FY '24, enabling growth towards I

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly provide specific figures or details regarding the current or expected order book or pending orders for Vimta Labs Limited as of May 2023. However, it mentions that certain divisions did not grow as anticipated, which affected margins, indicating variability in order fulfillment or demand. Capacity constraints exist, particularly in the pharma side, suggesting strong demand but limited ability to fully service orders at present. New capacity expansions are underway and expected to be operational by Q4 FY '24, which should help manage order backlog and support

IN US

Sale is live|00:00:00left today

Vimta Labs LtdQ1 FY23Healthcare Services

Vimta Labs Ltd Q1 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹598P/E: 25.6Market Cap: ₹2.0K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Margins expected to improve going forward, driven primarily by volume growth across businesses (Page 17).
→FY '24 growth target aims to improve upon last year's rate despite some capacity constraints, especially in pharma (Page 10).
→Pharma segment capacity is severely constrained currently but expected to be managed until new facilities come online by Q4 FY '24 (Page 17).
→Electronic and electrical testing division expected to scale up, potentially adding capacity (a chamber) by 2025-26, targeting INR30-40 crores revenue in a couple of years (Pages 9, 13).
→Food division expected to cross INR100 crores revenue soon, with margins improving as volumes scale (Pages 10, 14).
→Capacity expansion in Genome Valley (INR60 crores capex) completion by end FY '24 will support scaling towards INR500 crores midterm revenue target by 2026 (Pages 8, 11).
→Growth in pharma services, especially biologics/large molecules, expected with new technologies being commercialized from Q2 FY '24 (Page 17).
→Diagnostics growth to remain focused on B2B segment, with limited traction in B2C (Pages 8, 10, 16).

Margin guidance

Category 3

→Vimta Labs expects better margins going forward driven primarily by volume growth across business segments.
→FY '24 growth target aims to improve over FY '23 despite capacity constraints, with strong growth particularly in pharma and food testing.
→Preclinical & clinical research and large molecule services (biologics) are emerging as promising growth drivers.
→Electronics and electrical testing segment is expected to scale up steadily with capacity expansions planned by 2025-26.
→Capacity expansion in Genome Valley (INR 60 crores capex) to complete by end FY '24, enabling growth towards INR 500 crores revenue target by 2026.
→Operating leverage and volume ramp-up should positively impact margins and earnings, although some divisions underperformed last year.
→Strategically focusing on B2B diagnostics, which is more manageable and scalable.
→Overall, confident on midterm targets with growth in revenues, operating profits, and margins improving steadily.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has not indicated any current or planned new fundraising through debt or equity.
→The balance sheet remains net debt-free with cash and cash equivalents of INR398 million as of FY '23.
→During the year, Vimta Labs repaid INR44 million of debt, reducing outstanding borrowings to INR150 million, with a very low debt-to-equity ratio of 0.05x.
→Capital expenditure plans (around INR60 crores for capacity doubling at Genome Valley) are being funded from internal accruals and routine capex aligned with depreciation.
→No mention of raising funds externally for growth or capex was made; focus is on managing cash flow and working capital efficiently.
→Overall, the company is confident about funding its expansion through generated cash flows without resorting to external financing in the near future.

Order book

→The transcript does not explicitly provide specific figures or details regarding the current or expected order book or pending orders for Vimta Labs Limited as of May 2023.
→However, it mentions that certain divisions did not grow as anticipated, which affected margins, indicating variability in order fulfillment or demand.
→Capacity constraints exist, particularly in the pharma side, suggesting strong demand but limited ability to fully service orders at present.
→New capacity expansions are underway and expected to be operational by Q4 FY '24, which should help manage order backlog and support growth.
→Pharma large molecule services and diagnostics are areas of growing focus, likely implying incoming or expected orders post-installation of new technologies.
→The company is confident of growth prospects and capacity expansion to reach INR 500 crores revenue target by 2026, indicating a positive outlook on incoming order flow.

Capex plans

Yes

→Vimta Labs is undertaking a major capex of INR 60 crores to double capacities at the Genome Valley facility in Hyderabad, expected to complete by March FY '24. (Page 11, 16)
→This INR 60 crores capex is specifically for infrastructure/building expansion; equipment will be purchased as needed separately. (Page 7, 11)
→Approximately 20% of the INR 60 crores capex was spent in FY '23, with the remainder planned for FY '24. (Page 7)
→Additional ongoing annual capex aligns with depreciation expenses to buy new technologies, replace equipment, and expand capacities incrementally. (Page 7)
→Vimta Labs is also investing in new large molecule technologies (equipment presently being installed) to commercialize services from Q2 onward. (Page 17)
→Capacity constraints persist, especially in pharma; new facilities opening by Q4 FY '24 are expected to relieve pressure. (Page 17)
→The electronics and electrical testing division has had delayed scaling due to COVID, with plans to potentially add new chambers by 2025-26. (Page 13)

How does Vimta Labs Ltd rank vs peers in Healthcare Services?

Pro feature

1Vimta Labs Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Vimta Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio